- Home
- NVNO vs PTHL Comparison
NVNO vs PTHL Comparison
Compare NVNO & PTHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNO
- PTHL
- Stock Information
- Founded
- NVNO 1987
- PTHL 1998
- Country
- NVNO United States
- PTHL China
- Employees
- NVNO N/A
- PTHL N/A
- Industry
- NVNO Medical/Dental Instruments
- PTHL
- Sector
- NVNO Health Care
- PTHL
- Exchange
- NVNO Nasdaq
- PTHL Nasdaq
- Market Cap
- NVNO 58.9M
- PTHL 60.5M
- IPO Year
- NVNO N/A
- PTHL 2024
- Fundamental
- Price
- NVNO $3.15
- PTHL $3.59
- Analyst Decision
- NVNO
- PTHL
- Analyst Count
- NVNO 0
- PTHL 0
- Target Price
- NVNO N/A
- PTHL N/A
- AVG Volume (30 Days)
- NVNO 147.8K
- PTHL 49.9K
- Earning Date
- NVNO 02-27-2025
- PTHL 02-11-2025
- Dividend Yield
- NVNO N/A
- PTHL N/A
- EPS Growth
- NVNO N/A
- PTHL N/A
- EPS
- NVNO N/A
- PTHL N/A
- Revenue
- NVNO N/A
- PTHL $572,291.00
- Revenue This Year
- NVNO N/A
- PTHL N/A
- Revenue Next Year
- NVNO N/A
- PTHL N/A
- P/E Ratio
- NVNO N/A
- PTHL N/A
- Revenue Growth
- NVNO N/A
- PTHL 2.32
- 52 Week Low
- NVNO $2.45
- PTHL $3.32
- 52 Week High
- NVNO $6.97
- PTHL $6.45
- Technical
- Relative Strength Index (RSI)
- NVNO 46.80
- PTHL N/A
- Support Level
- NVNO $3.13
- PTHL N/A
- Resistance Level
- NVNO $3.68
- PTHL N/A
- Average True Range (ATR)
- NVNO 0.21
- PTHL 0.00
- MACD
- NVNO -0.01
- PTHL 0.00
- Stochastic Oscillator
- NVNO 8.20
- PTHL 0.00
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
About PTHL Pheton Holdings Ltd Class A Ordinary Shares
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.